NCT05525910View on ClinicalTrials.gov

Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 31, 2022

Primary Completion Date

November 7, 2022

Study Completion Date

November 7, 2022

Conditions
Biological AvailabilityHealthy Participants
Interventions
DRUG

Nirmatrelvir/ ritonavir

Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition

DRUG

Nirmatrelvir/ritonavir

Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition

DRUG

Nirmatrelvir/ritonavir

Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition

DRUG

Nirmatrelvir/ ritonavir

Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition

DRUG

Nirmatrelvir/ ritonavir

Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition

Trial Locations (1)

06511

New Haven Clinical Research Unit, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05525910 - Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants | Biotech Hunter | Biotech Hunter